Moderna, Inc. Restricted Cash
Moderna, Inc. (MRNA) had Restricted Cash of $4.00 million as of 2023-12-31, per its 10-K filed 2024-02-23.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCash · last filed 2024-02-23
- 2023-12-31: Restricted Cash $4.00M.
- 2023-09-30: Restricted Cash $4.00M.
- 2023-06-30: Restricted Cash $21.00M.
- 2023-03-31: Restricted Cash $20.00M.
| Period end | Restricted Cash |
|---|---|
| 2023-12-31 | $4.00M 10-K · filed 2024-02-23 |
| 2023-09-30 | $4.00M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $21.00M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $20.00M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $12.00M 10-K · filed 2024-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |